882856-83-9

Upstream product

• 882856-82-8 tert-butyl [(3R,4R)-1-[6-(aminocarbonyl)-5-nitropyridin-2-yl]-4-(2,4,5-trifluorophenyl)piperidin-3-yl]carbamate 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 882856-58-8 tert-butyl(3R,4R)-4-(2,4,5-trifluorophenyl)piperidin-3-ylcarbamate 
• 882856-76-0 tert-butyl (3R,4R)-1-benzyl-4-(2,4,5-trifluorophenyl)piperidin-3-ylcarbamate 
• 882856-64-6 dimethyl 2-cyano-3-(2,4,5-trifluorophenyl)pentanedioate 
• 888321-36-6 ethyl 3-(2,4,5-trifluorophenyl)acrylate 

Downstream Products

• 882856-84-0 tert-butyl [(3R,4R)-1-(2-methyl-4-oxo-3,4-dihydropyrido[3,2-d]pyrimidine-6-yl)-4-(2,4,5-trifluorophenyl)piperidin-3-yl]carbamate 

Relevant academic research and scientific papers

Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors

Substituted 3-aminopiperidines 3 were evaluated as DPP-4 inhibitors. The inhibitors showed good DPP-4 potency with superb selectivity over other peptidases (QPP, DPP8, and DPP9). Selected DPP-4 inhibitors were further evaluated for their hERG potassium ch

AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.